ArticleOpen forum infectious diseases2022
Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I).
Open access · goldAbstract read
In one paragraph
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 46 citations in OpenAlex.
- A 5-Year Population-Based Study of Polymicrobial Enterococcal Bloodstream Infection in Southeast Minnesota.Mayo Clinic proceedings · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium.Nature communications · 2026Article
- Characterization ofPHAGE (New Rochelle, N.Y.) · 2026Article
- ManagingEClinicalMedicine · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistantbioRxiv : the preprint server for biology · 2026Article
- Impact of Vancomycin Resistance on 30-Day Mortality in Solid Organ Transplant Recipients withAntibiotics (Basel, Switzerland) · 2026Article
- Genomics reveal Staphylococcus aureus persists during long-term urinary catheterization despite antimicrobial therapy and catheter exchanges.Nature communications · 2026Article
- Clinical and Genomic Characterization of Recalcitrant Enterococcal Bacteremia: A Multicenter Prospective Cohort Study (VENOUS).The Journal of infectious diseases · 2025Article
- Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.Antimicrobial agents and chemotherapy · 2025Review
- Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study.The Journal of antimicrobial chemotherapy · 2025Article
- A 5-Year Epidemiological Study of Monomicrobial Enterococcal Bloodstream Infection in a Population-Based Cohort.Open forum infectious diseases · 2025Article
- Genomic sequencing surveillance of patients colonized with vancomycin-resistant enterococci improves detection of healthcare-associated transmission.BMC global and public health · 2025Article
- Genomic epidemiology of vancomycin-resistant Enterococcus faecium in Eastern Denmark from 2020 to 2022, and identification of vanB Tn1549 insertion sites.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium ?Clinical orthopaedics and related research · 2025Observational
- Comparison of morbidity and mortality after bloodstream infection with vancomycin-resistant versus -susceptibleEmerging microbes & infections · 2024Article
- Sentinel Surveillance reveals phylogenetic diversity and detection of linear plasmids harboringAntimicrobial agents and chemotherapy · 2024Article
- Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics.Nature reviews. Microbiology · 2024Review
- Clinical characteristics, predisposing factors and outcomes for Enterococcus faecalis versus Enterococcus faecium bloodstream infections: a prospective multicentre cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
- Article
- ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.Nature reviews. Microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 16 institutions in 5 countries.
German A ContrerasDivision of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
Jose M MunitaCenter for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
Shelby SimarCenter for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
Courtney LuterbachDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, North Carolina, USA.
An Q DinhCenter for Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA.
Kirsten RydellDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Pranoti V SahasrabhojaneUniversity of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rafael RiosMolecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia.
Lorena DiazMolecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia.
Katherine ReyesDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Marcus ZervosDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-7328-4898
Helina M MisikirDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Gabriela Sanchez-PetittoDepartment of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Catherine LiuDepartment of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-7532-4822
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-9620-2525
Lilian M AbboDivision of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Luis ShimoseDivision of Infectious Disease, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Harald SeifertUniversity of Cologne, Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Cologne, Germany.
Carlota GudiolDepartment of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, l'Hospitalet de Llobregat, Barcelona, Spain.
Fernanda BarberisUnidad de Infectología, Sanatorio Dr Julio Méndez, Buenos Aires, Argentina.
Claudia PedrozaCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Samuel L AitkenCenter for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
Samuel A ShelburneCenter for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-4784-3227
Truc T TranCenter for Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA.
Blake M HansonCenter for Antimicrobial Resistance and Microbial Genomics, McGovern Medical School, University of Texas Health Science Center, Houston, Texas, USA.
Cesar A AriasCenter for Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA.
Henry Ford Hospital · USHouston Methodist · USThe University of Texas MD Anderson Cancer Center · USUniversidad El Bosque · COThe University of Texas Health Science Center at Houston · USUniversity of North Carolina at Chapel Hill · USCenter for Clinical Research (United States) · USInstituto de Salud Carlos III · ESMethodist Hospital · USUniversidad del Desarrollo · CLUniversity of Cologne · DEUniversity of Maryland, Baltimore · USUniversity of Miami · USUniversity of Mississippi Medical Center · USUniversity of Pittsburgh · USUniversity of Washington · US
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MProject 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MMolecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MNCATS NIH HHS UL1 TR003167NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI093749NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS UM1 AI104681
Abstract
backgroundVancomycin-resistant enterococci (VRE) are major therapeutic challenges. Prospective contemporary data characterizing the clinical and molecular epidemiology of VRE bloodstream infections (BSIs) are lacking.
methodsThe Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I) is a prospective observational cohort of adult patients with enterococcal BSI in 11 US hospitals. We included patients with
resultsForty-two of 232 (18%) patients died in hospital and 39 (17%) exhibited microbiological failure (lack of clearance in the first 4 days). Neutropenia (hazard ratio [HR], 3.13), microbiological failure (HR, 2.4), VRE BSI (HR, 2.13), use of urinary catheter (HR, 1.85), and Pitt BSI score ≥2 (HR, 1.83) were significant predictors of in-hospital mortality. Microbiological failure was the strongest predictor of in-hospital mortality in patients with
conclusionsFailure of early eradication of VRE from the bloodstream is a major factor associated with poor outcomes.
Indexed as
bacteremiaEnterococcusVRE
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.